Abstract
When pharmacological treatment is needed to reach control of gestational diabetes mellitus (GDM), insulin is still first-line agent but metformin has been progressively pointed as an effective alternative. Our aim is to confirm whether metformin is an effective and safe option to insulin, by comparing maternal and foetal outcomes between women with GDM treated with these drugs. Retrospective study including 399 women with GDM, 135 needing pharmacological treatment. Comparison of demographic features, risk factors for GDM, maternal and foetal outcomes between women treated with insulin (G1, 41/135) and those treated with metformin (G2, 94/135). X2/Fisher tests were performed. Significance was set at p < 0.05. Both groups showed similar features and risk factors for GDM, except for chronic hypertension, more prevalent in G1. Therapy with insulin showed poorer metabolic control with higher rate of pregnant with HbA1c ≥ 6% (42 mmol/mol) (25.6 vs 4.5%, p = 0.001) and more polihydramnios (14.6% vs 3.2%, p = 0.023). A higher rate of caesarean was observed in G1, however, with no statistical difference (42.5% vs 26.9%, p = 0.076). There were more newborns weighing < 2500 g in women treated with metformin. No other outcome showed difference with statistical significance, namely maternal weight gain, macrosomia or neonatal comorbidities. Metformin allowed a good metabolic control with maternal and foetal outcomes similar to insulin. Metformin has proven effective as a pharmacological option to insulin. Prospective and randomized studies are needed as well as evaluation of long term benefits of metformin.
Similar content being viewed by others
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
References
American Diabetes Association (2018) 13. Management of diabetes in pregnancy: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl. 1): S137–S143. https://doi.org/10.2337/dc18-S013.
García-Patterson A, Balsells M, Yamamoto JM, Kellett JE, Solà I, Gich I, et al. Usual dietary treatment of gestational diabetes mellitus assessed after control diet in randomized controlled trials: subanalysis of a systematic review and meta-analysis. Acta Diabetol. 2019;56(2):237–40. https://doi.org/10.1007/s00592-018-1238-4.
Schellong K, Schulz S, Harder T, Plagemann A. Birth weight and long-term overweight risk: systematic review and a meta-analysis including 643,902 persons from 66 studies and 26 countries globally. PLoS One. 2012;7(10):e47776. https://doi.org/10.1371/journal.pone.0047776.
Koivusalo SB, Rönö K, Klemetti MM, et al. Gestational diabetes mellitus can be prevented by lifestyle intervention: the Finnish Gestational Diabetes Prevention Study (RADIEL): a randomized controlled trial. Diabetes Care. 2016;39:24–30. https://doi.org/10.2337/dc15-0511.
Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005;192:989–97. https://doi.org/10.1016/j.ajog.2004.11.039.
Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013;159:123–9. https://doi.org/10.7326/0003-4819-159-2-201307160-00661.
Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339–48. https://doi.org/10.1056/NEJMoa0902430.
Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. (2005) Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352(24):2477–2486. https://doi.org/10.1056/NEJMoa042973.
Almeida MC, Dores J, Ruas L, et al. Consensos “Diabetes Gestacional”—Atualização 2017. Revista Portuguesa de Diabetes. 2017;12(1):24–38.
Society of Maternal-Fetal Medicine Publications Committee. SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018;218(5):B2–4. https://doi.org/10.1016/j.ajog.2018.01.041.
Kelley KW, Carroll DG, Meyer A. A review of current treatment strategies for gestational diabetes mellitus. Drugs Context. 2015;4:212282. https://doi.org/10.7573/dic.212282.
NICE Guideline. Diabetes in pregnancy: management from preconception to the postnatal period. Available at https://www.nice.org.uk/guidance/ng3 [Last accessed: November, 2019].
Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102. https://doi.org/10.1136/bmj.h102.
Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One. 2013;8(5):e64585. https://doi.org/10.1371/journal.pone.0064585.
The HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome. N Engl J Med. 2008;358:1991–2002. https://doi.org/10.1056/NEJMoa0707943.
International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care. 2010;33(3):676–82. https://doi.org/10.2337/dc09-1848.
Rasmussen KM, Yaktine AL. Guidelines for weight gain during pregnancy, Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines. Washington, DC: The National Academies Press; 2009.
Cunha M, Marques A, Carreiro H, Machado MC (2007) Percentile of birth weight and gestational age, in a newborn population. Acta Pediatr Port 2007:38(5):187–193.
Immanuel J, Simmons D (2017) Screening and treatment for early-onset gestational diabetes mellitus: a systematic review and meta-analysis. Curr Diab Rep 2017;17(11):115. https://doi.org/10.1007/s11892-017-0943-7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval/Informed Consent
Data was collected as required by the Diabetes and Pregnancy Study Group (Grupo de Estudo de Diabetes e Gravidez), responsible for the national database; diagnosis and treatment followed national and international guidelines. There was no use of experimental or new protocols; being a retrospective observational and non-interventional study where anonymity is granted, informed consent was considered not to be a requirement. The article was submitted to the Hospital’s Ethics for Health Comitee (Comissão de Ética para a Saúde do Hospital Beatriz Ângelo) evaluation and it was approved.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Medicine
Rights and permissions
About this article
Cite this article
Morais Rodrigues, I., Figueiredo, A., Pereira, N. et al. Metformin as a Safe Option to Insulin in Gestational Diabetes Mellitus: a Retrospective Study. SN Compr. Clin. Med. 2, 272–277 (2020). https://doi.org/10.1007/s42399-020-00229-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42399-020-00229-9